echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > PD-1 monoantimmune Opdivo new assisted treatment of non-small cell lung cancer, phase 3 clinical benefits.

    PD-1 monoantimmune Opdivo new assisted treatment of non-small cell lung cancer, phase 3 clinical benefits.

    • Last Update: 2020-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Phase 3 clinical trial CheckMate-816 evaluated the efficacy of Opdivo (nivolumab) in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) that could be removed before surgery.
    the trial group received three doses of Opdivo plus chemotherapy before surgery.
    results showed that Opdivo combined chemotherapy reached the primary endpoint of pathological complete remission (pCR), with a higher proportion of patients in the group receiving combination therapy not detecting tumor cells in surgically removed tissue than in the placebo treatment group.
    CheckMate-816 means that Opdivo of BMS became the first immunotherapy in Phase 3 clinical trials, in combination with chemotherapy, to significantly improve the efficacy of patients with pre-surgery NSCLC removal.
    CheckMate-816 is still in progress and will continue to evaluate another major endpoint of the trial, the time patients remain cancer-free or deteriorating, and other critical secondary endpoints.
    : This means That Opdivo has beaten a number of competitors in the NSCLC's new complementary treatments, including Mercedon's PD-1 single-anti-Keytruda, Roche's PD-L1 single-anti-Tecentriq and AstraZenecom's PD-L1 single-anti-Imfinzi.
    Although Opdivo has been approved for the treatment of metastasis NSCLC patients, earlier treatment may give it an advantage over Merck's Keytruda, which dominates the late NSCLC field.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.